论文部分内容阅读
来自英国的一项研究报告表明,与美洛昔康(Meloxicam)相比较,罗非昔布(Rofecoxib)和塞来昔布(Celecoxib)增加了发生脑血管血栓的危险,但是减少了其他方面的药品不良反应(ADRs)。他们采用处方监测的方法,在药品进入销售市场后即进行处方监控,两组研究比较了这些药物的安全性。一
A study from the UK showed that Rofecoxib and Celecoxib increased the risk of developing cerebrovascular thrombosis compared with Meloxicam but reduced other aspects of Adverse drug reactions (ADRs). They employ prescription monitoring methods to monitor the prescription of drugs as they enter the marketing market. Two groups of studies have compared the safety of these drugs. one